• However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC) in adult MDS patients. (medscimonit.com)
  • For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used. (wikipedia.org)
  • The oral BCL-2 inhibitor venetoclax in combination with a hypomethylating agent (i.e. azacitidine or decitabine) has recently become a paradigm-shifting new standard of care for older patients with AML who are ineligible for intensive chemotherapy. (lls.org)
  • A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malign. (sparkcures.com)
  • However, the availability within the past decade of 3 drugs, azacitidine, lenalidomide, and decitabine, 3 - 5 which were approved by the FDA specifically for the treatment of MDS, has partly spurred the maturation rate of epidemiologic knowledge. (jnccn.org)
  • Hypomethylating agents (HMAs) such as decitabine (DEC) or azacitidine (AZA) are FDA approved therapies for patients with different myeloid malignancies as single agent or in combination with venetoclax. (astx.com)
  • Venetoclax (Ven), a Bcl-2 specific BH3 mimetic has demonstrated anticancer efficacy, and is indicated in combination with azacitidine, decitabine or low-dose cytarabine to treat newly-diagnosed AML in adults age 75 years or older. (emadicancerlab.com)
  • Although preclinical studies indicate that decitabine is usually a more potent antileukemic agent than azacitidine [40, 41], the clinical data suggest that azacitidine is more effective than decitabine. (giknet.org)
  • Currently, there are limited FDA-approved therapies for MDS, which include hypomethylating agents such as azacitidine and decitabine, iron chelators such as deferasirox, and lenalidomide. (medscape.com)
  • During anamnesis, lower urinary tract and gynecological cycles of decitabine, it was decided to switch AML therapy to surgeries, obstetrical history, neurological disorders, diabetes, azacitidine associated with venetoclax, without new reports and trauma were excluded as possible causes of urinary of urinary retention (Figure 1 ). (bvsalud.org)
  • This approval is significant because data from our VIALE-A trial has shown that newly-diagnosed patients, who cannot undergo intensive chemotherapy, lived longer when treated with VENCLEXTA plus azacitidine than those treated with azacitidine alone," said Mohamed Zaki , M.D., Ph.D., vice president and global head of oncology development, AbbVie. (biospace.com)
  • Additionally, patients in the VENCLEXTA plus azacitidine arm achieved a complete remission (CR) rate of 37% (95% CI: 31%, 43%) with a median duration of CR of 18.0 months (95% CI: 15.3, -) compared with patients in the placebo plus azacitidine arm with a CR rate of 18% (95% CI: 12%, 25%) with a median duration of CR of 13.4 months (95% CI: 8.7, 17.6). (biospace.com)
  • Phase 2 evaluated INCB052793 or itacitinib plus azacitidine in DNA methyltransferase inhibitor (DNMTi)-refractory AML or MDS. (elsevierpure.com)
  • The most common reasons for treatment discontinuation were progressive disease (35.4% and 50.0%) and adverse events (22.9% and 20.0%) for INCB052793 and itacitinib plus azacitidine, respectively. (elsevierpure.com)
  • Conclusion: Inhibition of JAK1 with INCB052793 (monotherapy or combination therapy) or itacitinib plus azacitidine did not demonstrate clinically meaningful responses in these patients with hematopoietic malignancies. (elsevierpure.com)
  • Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. (onclive.com)
  • Thomas Cluzeau, MD, PhD, head of hematology department, Central University Hospital of Nice, in Nice, France, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53 -mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (onclive.com)
  • This custom health technology review will summarize evidence on the efficacy and safety of Azacitidine (intravenous and subcutaneous) as maintenance therapy for patients with Acute Myeloid Leukemia. (cadth.ca)
  • The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS). (slu.edu)
  • The primary objectives of this study are to compare the efficacy of magrolimab + venetoclax + azacitidine versus placebo + venetoclax + azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. (slu.edu)
  • Scholars@Duke publication: Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia. (duke.edu)
  • Aim: Evaluate the relative efficacy of oral versus injectable azacitidine (AZA) maintenance therapy in acute myeloid leukemia (AML) after complete remission. (duke.edu)
  • ONUREG ® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. (onuregpro.com)
  • Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). (wikipedia.org)
  • We report a survival case of invasive splenic mucormycosis involving the liver caused by Rhizopus microsporus in a patient during consolidation therapy for acute monocytic leukemia (AML-M 5 ). (frontiersin.org)
  • PURPOSE: Infections due to severe neutropenia are the most common therapy-associated causes of mortality in patients with acute myeloid leukemia (AML). (bvsalud.org)
  • A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or. (sparkcures.com)
  • Chimeric Therapeutics expects a phase-1B clinical trial into its "natural killer" cell therapy for newly-diagnosed patients with acute myeloid leukemia to be open for new enrolments before the end of the year. (businessnews.com.au)
  • Chimeric Therapeutics is about to begin its second cell therapy trial for patients with acute myeloid leukemia. (businessnews.com.au)
  • Phase 1b evaluated INCB052793 plus standard therapy in relapsed/refractory multiple myeloma, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS). (elsevierpure.com)
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML). (wapakdailynews.com)
  • Uproleselan (yoo' pro le'se lan), currently in a comprehensive Phase 3 development program in acute myeloid leukemia (AML), received Breakthrough Therapy designation from the U.S. FDA and from the Chinese National Medical Products Administration for treatment of adult AML patients with relapsed or refractory disease. (wapakdailynews.com)
  • In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). (biomedcentral.com)
  • Between September 2017 and July 2020, six R/R ALAL-NOS patients at our hospital, who fulfilled the criteria of ALAL-NOS according to the 2016 World Health Organization (WHO) classification, were treated with venetoclax-based regimen (venetoclax combined with azacitidine or chemotherapy). (biomedcentral.com)
  • A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575. (sparkcures.com)
  • Objective: Report final safety/tolerability and efficacy data. (ox.ac.uk)
  • This Phase Ib/II clinical trial evaluates safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and low-dose cytarabine (LDAC) in patients with treated secondary AML. (wapakdailynews.com)
  • This Phase I study is evaluating the safety, tolerability, and preliminary efficacy of uproleselan in combination with azacitidine (Aza) and Venetoclax (Ven) in patients with untreated AML who were unfit for intensive chemotherapy. (wapakdailynews.com)
  • Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. (nih.gov)
  • Context: Magrolimab is a monoclonal antibody blocking CD47, a "don't eat me" signal overexpressed on cancer cells, which leads to tumor phagocytosis and is synergistic with azacitidine. (ox.ac.uk)
  • Due to substantial differences in the pharmacokinetic parameters, the recommended dose and schedule for ONUREG ® are different from those for the intravenous or subcutaneous azacitidine products. (onuregpro.com)
  • Treatment of patients using intravenous or subcutaneous azacitidine at the recommended dosage of ONUREG ® may result in a fatal adverse reaction. (onuregpro.com)
  • Treatment with ONUREG ® at the doses recommended for intravenous or subcutaneous azacitidine may not be effective. (onuregpro.com)
  • Do not substitute ONUREG ® for intravenous or subcutaneous azacitidine. (onuregpro.com)
  • The indications and dosing regimen for ONUREG differ from that of intravenous or subcutaneous azacitidine ( 2.1 , 5.1 ). (nih.gov)
  • Of 23 patients in the study, 52% had at least two prior therapies, 52% had received prior intensive therapies, 22% had prior allogeneic stem cell transplant, and 43% had prior exposure to tagraxofusp. (medpagetoday.com)
  • They then used preclinical models to compare the efficacy of these allogeneic CAR T cells to the autologous CAR T cells typically used in treatment. (liangyihui.net)
  • Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. (nih.gov)
  • Design: Ph1b trial of magrolimab+azacitidine (NCT03248479). (ox.ac.uk)
  • Conclusions: Magrolimab+azacitidine was well tolerated, with promising efficacy in patients with untreated HR MDS, including those with TP53-mutated and -wild-type disease. (ox.ac.uk)
  • Standard care for MDS is constantly changing, but it typically includes supportive therapy, including transfusions, and may include bone marrow stimulation and cytotoxic chemotherapy or hypomethylating agents. (medscape.com)
  • In addition to myeloid malignancies, azacitidine is also being investigated in lymphoid malignancies such as relapsed aggressive B-cell lymphomas (DLBCL-001 trial, "type":"clinical-trial","attrs":"text":"NCT02343536″,"term_id":"NCT02343536″NCT02343536) or T-cell lymphomas in combination with chemotherapy and other agents such as proteosome inhibitors like bortezomib or HDAC inhibitors like romidepsin. (giknet.org)
  • 3 , 4 Since 2020, older or unfit patients are treated by a non-intensive approach combining the hypomethylating agent azacitidine and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax given orally until progression. (dovepress.com)
  • This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. (slu.edu)
  • Home 1 / ASTX727 - Oral HMA (MDS) 2 / 2019 3 / 2019 ASH - Pharmacokinetic Exposure Equivalence and Preliminary Efficacy. (astx.com)
  • The studies describe safety and preliminary efficacy in frontline unfit and treated secondary AML populations not previously studied with this novel investigational agent," said Edwin Rock, M.D., Ph.D., Chief Medical Officer. (wapakdailynews.com)
  • we compared high- and intermediate-dose cytarabine administration on days 1, 2, and 3 (AC-123) versus days 1, 3, and 5 (AC-135) in consolidation therapy of AML. (bvsalud.org)
  • The study is the first clinical trial to evaluate the synergy of Chimeric's "CHM 0201 NK" cells in combination with the current standard of care that delivers Azacitidine and Venetoclax to AML patients. (businessnews.com.au)
  • As the trial progresses beyond dose confirmation, it will also become the first to evaluate cellular therapy in newly-diagnosed AML patients. (businessnews.com.au)
  • TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations. (slu.edu)
  • The observed safety profile was generally consistent with the known safety profile of VENCLEXTA in combination with azacitidine. (biospace.com)
  • A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination W. (sparkcures.com)
  • The company's off-the-shelf NK cell platform successfully demonstrated safety and efficacy during the phase-1A trial that was completed at the Seidman Cancer Centre in Ohio last year. (businessnews.com.au)
  • Management says data from the complete phase-1A clinical trial was published in March last year, demonstrating safety and efficacy in blood cancers and solid tumours. (businessnews.com.au)
  • All patients received C-DEC in all subsequent cycles from Cycle 3 onwards until treatment discontinuation to study clinical efficacy and safety of C-DEC. Patients were eligible as per the FDA-approved label (MDS IPSS Intermediate [Int]-1,-2 or high risk[HR] and CMML patients). (astx.com)
  • Pemmaraju presented a study at the recent American Society of Hematology's virtual meeting evaluating the safety and efficacy of IMGN632 in patients with relapsed/refractory BPDCN. (medpagetoday.com)
  • cerning efficacy and safety of ribavirin are scarce ( 12 ). (cdc.gov)
  • Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. (cdc.gov)
  • A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety. (cdc.gov)
  • While these therapies are not curative on their own, my hope is that this combination will lead to a practice changing all-oral, outpatient, and well-tolerated curative strategy for patients with IDH-mutated AML. (lls.org)
  • Patients with AML harboring IDH1 or IDH2 mutations respond particularly well to venetoclax-combination therapy, with a remission rate of ~70% and median survival of 24 months. (lls.org)
  • Yet despite these "favorable outcomes", relapse is nearly inevitable and the outcomes of patients at the time of venetoclax-combination therapy are particularly dismal. (lls.org)
  • A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysp. (sparkcures.com)
  • Therefore, novel drugs and targets are being explored as mono-or combination-therapy in this field. (pvreporter.com)
  • Ongoing work in our lab us focused on investigating the potential of Ven-PegC as well as other PegC-based combination therapies in xenograft and syngeneic models of pancreatic cancer. (emadicancerlab.com)
  • Given that glutaminolysis has been shown as a targetable vulnerability of AML undergoing FLT3i therapy, the Emadi lab is investigating the impact of targeting glutamine metabolism in FLT3i-resistant AML to develop novel combination therapies that can be translated to the clinic. (emadicancerlab.com)
  • This review includes a short overview of the most important preclinical approaches as well as an extensive discussion of medical tests using epigenetic combination therapies in NSCLC, including ongoing tests. (unambitiousus.com)
  • Relationships of platelet glycoprotein specific antibody with therapeutic efficacy of short-term high-dose dexamethasone and bleeding score in the newly diagnosed adult patients with primary immune thrombocytopenia. (cdc.gov)
  • The INSPIRE trial, which has now reached full accrual, is studying the experimental agent rigosertib to determine if it can significantly prolong the survival of these patients when compared to physician's choice of therapy. (onconova.com)
  • Data of the six patients was collected and analyzed, including clinical characteristics, cytogenetics, gene mutation profile, prior therapy, complete remission (CR) rate, overall survival (OS, survival duration was defined from diagnosis of the disease to dead). (biomedcentral.com)
  • Efficacy was based on the rate of CR and duration of CR with supportive evidence of rate of CR + complete remission with partial hematologic recovery (CR+CRh), duration of CR+CRh, and the rate of conversion from transfusion dependence to transfusion independence. (biospace.com)
  • Introduction: Patients (pts) with primary refractory or relapsed high-grade lymphoma (HGL) including Burkitt lymphoma (BL) and high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 (double-hit lymphoma, DHL) have a dismal prognosis with patients almost never achieving a meaningful remission to second line therapy. (bvsalud.org)
  • Conclusion: In AML, maintenance therapy with oral AZA was associated with improved OS versus injectable AZA. (duke.edu)
  • Improving the convenience of leukemia therapy with oral and primarily outpatient treatment regimens are also particularly valuable to enhance patient satisfaction. (lls.org)
  • Also, the oral formulation of azacitidine is currently being tested in a phase III trial for continuous administration and extended low dose schedules as a maintenance therapy in AML (Quazar AML-001 trial, "type":"clinical-trial","attrs":"text":"NCT01757535″,"term_id":"NCT01757535″NCT01757535) as well as for lower-risk MDS patients with low platelet counts (AZA-MDS-003 trial, "type":"clinical-trial","attrs":"text":"NCT01566695″,"term_id":"NCT01566695″NCT01566695). (giknet.org)
  • Mucormycosis is a rare but life-threatening opportunistic fungal infection associated with immunocompromised patients with hematologic malignancies, persistent neutropenia, poorly controlled diabetes mellitus, iron overload, and trauma, undergoing solid organ or hematopoietic stem cell transplantation (HSCT), or receiving corticosteroid therapy ( 1 ). (frontiersin.org)
  • This case aims to emphasize the importance of utilizing mNGS and CEUS for the timely diagnosis of mucormycosis to help clinicians identify splenic mucormycosis and initiate appropriate therapy as soon as possible to improve therapeutic efficacy and prognosis. (frontiersin.org)
  • The aim of this case is to emphasize the importance of utilizing mNGS and CEUS in the diagnosis of mucormycosis to help clinicians identify splenic mucormycosis and initiate appropriate therapy as soon as possible to improve therapeutic efficacy and prognosis. (frontiersin.org)
  • Therefore, we are providing an overview of what lies ahead in the field of epigenetic combinatory therapies of NSCLC in the coming years. (unambitiousus.com)
  • Despite continuous study and development of fresh restorative regimens, the 5-12 months overall survival (OS) rate of non-small cell lung malignancy (NSCLC) remains at a mere 15%.1 Epigenetic therapy approaches offer novel, innovative treatment options that may improve this troubling statistic, namely with DNA methyltransferase inhibitors (DNMTi) and histone-modifying agents. (unambitiousus.com)
  • Posttranslational modifications, such as addition or removal of methyl or acetyl organizations to amino acids within the histones, can lead to a change of conformation and therefore facilitate or hinder access of the transcription element machinery to the DNA.4,5 Reversing the aberrant epigenetic patterns of cancer cells can re-sensitize them to founded treatment, e.g., chemotherapeutics or radiation therapy. (unambitiousus.com)
  • Mutations in other genes involved in epigenetic regulation, such as mutations is usually predictive for response to azacitidine in MDS, although as expected mutated patients have a poor overall survival despite response [74]. (giknet.org)
  • A detailed description of epigenetic therapy (including AZN) in solid tumors has recently been reviewed [88]. (giknet.org)
  • Patients enrolled in the study were treated with APR-246 at 4500 mg intravenously from days 1 to 4 followed by azacitidine at 75mg/m2 from days 4 to 10 in 28-day cycles. (onclive.com)
  • CONCLUSION: Our numerical study supports the use of AC-123 plus G-CSF as standard conventional AML consolidation therapy to reduce the risk for life-threatening infectious complications. (bvsalud.org)
  • The study was terminated for lack of efficacy. (elsevierpure.com)
  • tradename Elzonris) is a CD123 targeting agent that showed efficacy in this small pilot study . (medpagetoday.com)
  • A study by Tang et al has determined that long-term TKI therapy may reduce the abundance of leukemic stem cells in select patients. (medscape.com)
  • A study by Costa et al found a potential use for the hypomethylating drug azacitidine in CML, although further research is needed. (medscape.com)
  • ONUREG ® is contraindicated in patients with known severe hypersensitivity to azacitidine or its components. (onuregpro.com)
  • Given the paucity of effective therapies for CMML, delineating the molecular mechanisms of ASXL1 -mutant CMML (ASXL1 MT ) is of particular interest from a therapeutic standpoint. (nature.com)
  • Early identification and prompt initiation of targeted antifungal therapy are essential to improving the patient's prognosis. (frontiersin.org)
  • However, while they show significant efficacy, these patients continue to have an overall poor prognosis. (giknet.org)
  • The HR is from a Cox proportional hazards model stratified by age (55 to 64 vs ≥65 years), cytogenetic risk category at time of induction therapy (intermediate risk vs poor risk), and received consolidation therapy (yes vs no). (onuregpro.com)
  • The induction therapy for ALAL-NOS often refers to ALAL treatment. (biomedcentral.com)
  • In Arm B, participants will receive the best available therapy (BAT) for MF. (slu.edu)
  • The efficacy of venetoclax was tested in a single-arm clinical trial of 106 participants with CLL who have a 17p deletion and who had received at least one prior therapy. (wikipedia.org)
  • Approval was based on MURANO (NCT02005471), a randomized (1:1), multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 participants with CLL who had received at least one prior line of therapy. (wikipedia.org)
  • Activity of these inhibitors depends on their mechanism of receptor binding (active vs inactive conformation) and efficacy against the FLT3-ITD and -TKD mutations (type 1 inhibitors are active both on FLT3 -ITD and TKD, whereas type 2 inhibitors are active only on FLT3 -ITD). (dovepress.com)
  • 65 years), therapy-related AML and AML with myelodysplasia (MDS)-related changes, reaching about 30-35% of cases, while in complex-karyotype AML the TP53 mutation rate rockets up to 70% of cases [ 5 ] . (encyclopedia.pub)
  • AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. (aamds.org)
  • Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. (aamds.org)
  • Although the impact of FLT3 -ITD mutation is unclear in the context of venetoclax-azacitidine treatment, 6 the negative impact of FLT3 -ITD on survival of AML patients treated with ICT is well established. (dovepress.com)
  • In 2015, the United States Food and Drug Administration (FDA) granted the breakthrough therapy designation to venetoclax for people with CLL or SLL who have relapsed, become intolerant to, or refractory to previous treatment. (wikipedia.org)
  • This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. (mds-foundation.org)
  • Thus, further improvements to available treatment regimens are needed to augment efficacy and potentially overcome resistance patterns, which may provide enduring leukemia cures. (lls.org)
  • This is especially true in the treatment of young patients with radiation therapy. (mdanderson.org)
  • Ongoing phase II/III trials are also examining the administration of azacitidine for the prevention or treatment of relapse in patients after hematopoietic stem cell transplantation (RELAZA trial, "type":"clinical-trial","attrs":"text":"NCT01462578″,"term_id":"NCT01462578″NCT01462578). (giknet.org)
  • JAK1-regulated cytokines stimulate proliferation and growth of malignant cells and resistance to certain therapies. (elsevierpure.com)
  • While the development of potent FLT3 inhibitors has improved outcome, responses are usually short-lived and acquired resistance to FLT3i therapy remains a challenge. (emadicancerlab.com)
  • We highlight current limitations for the success and durability of azanucleoside-based therapy and illustrate that a better understanding of the molecular determinants of drug response holds great potential to overcome resistance. (giknet.org)
  • More commonly, multidrug regimens incorporating drugs with different mechanisms of action and different toxicities are used to increase efficacy, reduce dose-related toxicity, and decrease the probability of drug resistance. (msdmanuals.com)
  • Saint Louis University School of Medicine faculty in hematology, oncology, and cellular therapy are committed to leadership in clinical research programs. (slu.edu)
  • The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy . (sparkcures.com)
  • The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy . (sparkcures.com)
  • or gemcitabine plus erlotinib however their anti-tumor effects are remarkably lower than for other solid tumors, and there is currently no chemotherapeutic regimen that provides meaningful clinical outcome beyond the first salvage therapy, underscoring the urgent need for novel therapeutic strategies. (emadicancerlab.com)
  • Given the national shortage of neonatal intensive care unit (NICU)-based psychological services, group therapy is a potentially viable and cost-effective way to deliver care. (bvsalud.org)
  • The major modalities of therapy are Surgery (for local and local-regional disease) Radiation. (msdmanuals.com)